NCT04243031 is a clinical trial of QFT Access in Tuberculosis (TB), sponsored by QIAGEN Gaithersburg, Inc.

Who is sponsoring NCT04243031?

NCT04243031 is sponsored by QIAGEN Gaithersburg, Inc.

What drugs are being tested in NCT04243031?

Interventions in NCT04243031: QFT Access.

What condition does NCT04243031 study?

NCT04243031 studies Tuberculosis (TB).

Is NCT04243031 still recruiting?

NCT04243031 is currently withdrawn. Last updated 16 September 2020.

Last reviewed 2020-09-16 · How we verify

NCT04243031

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

QuantiFERON Access Clinical Performance Study Protocol

Withdrawn Last updated 16 September 2020

What this trial tests

trial testing QFT Access in Tuberculosis (TB). Withdrawn.

Timeline

1 April 2020

Primary endpoint
1 August 2020

1 November 2020

Quick facts

Lead sponsor	QIAGEN Gaithersburg, Inc
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	1 April 2020
Primary completion	1 August 2020
Estimated completion	1 November 2020

Drugs / interventions tested

QFT Access

Conditions studied

Tuberculosis (TB) — all drugs for Tuberculosis (TB) →

Sponsor

QIAGEN Gaithersburg, Inc — full company profile →

Who can join

18 and older, any sex, with Tuberculosis (TB). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Approximately 225 samples, obtained from participants with varying risk factors for TB infection and disease, will be tested using the QFT Access Kit and the comparator device QFT-Plus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Tuberculosis (TB)

Currently open trials in the same condition.

NCT06963606 — Effectiveness of Computer-Aided Detection Chest X-Ray Screening for Improving Tuberculosis Diagnostic Yield in Chinese P · NA · recruiting
NCT07178860 — Respiratory Health and Wellbeing Post Pulmonary Tuberculosis · recruiting
NCT06909799 — A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease · NA · recruiting
NCT06997367 — Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV16 · Phase 2 · active not recruiting
NCT06916962 — Examining Psycho-Socioeconomic Linkages in TB Care: The UPLIFT Trial · NA · recruiting

Other QIAGEN Gaithersburg, Inc trials

Trials by the same sponsor.

NCT06360757 — Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19) · terminated
NCT06645236 — DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit · NA · recruiting
NCT05305534 — QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study · completed
NCT05733559 — QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study · completed
NCT06681025 — Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04243031 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by QIAGEN Gaithersburg, Inc
Last refreshed: 16 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04243031.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing